Overview

The only comprehensive academic program of its kind on Long Island, Stony Brook’s fast-growing Breast Care Program treats more than 450 new patients with breast cancer annually with the most advanced treatment available. At the Carol M. Baldwin Breast Care Center, located in the new Cancer Center outpatient facility, breast imaging specialists perform more than 8,000 mammograms and 2,000 sonograms a year. The program also makes available a highly specialized genetic counselor for women who may have inheritable breast cancer. And, in conjunction with the Department of Physical Therapy, women have access to a comprehensive, highly specialized lymphedema evaluation and treatment program.

The Breast Care Center has been a pioneer in a number of ways, including being the first on Long Island to offer digital mammography and being one of only seven centers in the world equipped with a tomosynthesis machine. This experimental technology, which produces 3D mammogram images—ideal for women with dense breasts—is still in the testing stage. In addition, Stony Brook’s breast cancer surgeons specialize in breast conservation surgery, and were the first on Long Island to offer the less invasive sentinel node biopsy, widely considered the biggest advance in breast cancer surgery in the past several years.

Highlights

- **Stony Brook’s breast surgeons and radiation oncologists are using the new mammosite radiation system,** which involves temporary implantation of a device into the lumpectomy cavity, which can then assist in delivering full lumpectomy radiation in five days instead of the traditional six weeks of external radiation to the entire breast. The department also provides partial breast radiation via 3D conformal radiotherapy given in a series of 10 treatments over five days. This can be used with select patients with left-side breast cancer, where minimizing radiation doses to the heart and lung is critical.

- **Oncologists are using standard and novel chemotherapy regimens**—as well as new combinations that can dramatically improve survival rates—with the goal of becoming the standard regimen of the future. The program can also connect patients with resistant tumors to phase II experimental agents.

- **Stony Brook participates in a wealth of clinical trials and basic research.** One study, called TAILORx Trial (Trial Assigning Individualized Options for Treatment), looks at genetic profiling of tumors to determine which patients need chemotherapy. Other basic research projects look to gain a greater understanding of the biology of the breast and developing leading-edge treatments.

TEAM MEMBERS

**Surgery:** Brian O’Hea, MD, Team Leader and Director, Carol M. Baldwin Breast Care Center; Martyn Burk, MD; Patricia Farrelly, MD; Louis Merriam, MD; Colette Pameijer, MD; Trisha Fideli, RN; and Lynette LeePack-May, NP

**Breast Imaging:** Jayne M. Bernier, MD; Cliff Bernstein, MD; Sheri Ford, MD; and Roxanne Palermo, MD

**Medical Hematology/Oncology:** Andrzej Kudelka, MD; Janice Lu, MD; and Neetu Radhakrishnan, MD

**Pathology:** Jingxuan Liu, MD

**Breast Imaging:** Jayne M. Bernier, MD; Cliff Bernstein, MD; Sheri Ford, MD; and Roxanne Palermo, MD

**Medical Hematology/Oncology:** Andrzej Kudelka, MD; Janice Lu, MD; and Neetu Radhakrishnan, MD

**Pathology:** Jingxuan Liu, MD

**Plastic and Reconstructive Surgery:** Duc Bui, MD, and Sami Kahn, MD

**Radiation Oncology:** Allen G. Meek, MD, Chair, Department of Radiation Oncology, and Tae Park, MD